Abstract | BACKGROUND: PATIENTS AND METHODS: Patients with advanced urothelial cancer who underwent gemcitabine/ cisplatin (GC) split or gemcitabine/ carboplatin (GCarbo) for renal dysfunction with a glomerular filtration rate of approximately 40-60 ml/min between 2008 and 2015 were chosen and reviewed using their charts. Patients with normal renal function treated with GC were also reviewed as a reference group. RESULTS: A total of 41 patients, including 10 treated with GCsplit, 16 treated with GCarbo, and 15 treated with GC, were analyzed. The median overall and progression-free survival in GCsplit and GCarbo groups were 18.1 and 12.5 months (p=0.0454) and 9.9 and 6.4 months (p=0.0404), respectively. Neutropenia was relatively more severe in the GCsplit group than the GCarbo group (p=0.0103). CONCLUSION: GCsplit may be a better treatment option for patients with advanced urothelial cancer with cisplatin-ineligible renal function. However, a prospective randomized controlled trial with a large-sized population is warranted to confirm our preliminary results.
|
Authors | Kouji Izumi, Hiroaki Iwamoto, Hiroshi Yaegashi, Kazuyoshi Shigehara, Takahiro Nohara, Yoshifumi Kadono, Atsushi Mizokami |
Journal | In vivo (Athens, Greece)
(In Vivo)
2019 Jan-Feb
Vol. 33
Issue 1
Pg. 167-172
ISSN: 1791-7549 [Electronic] Greece |
PMID | 30587618
(Publication Type: Clinical Trial, Journal Article)
|
Copyright | Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved. |
Chemical References |
- Deoxycytidine
- Carboplatin
- Cisplatin
- Gemcitabine
|
Topics |
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage, adverse effects)
- Carboplatin
(administration & dosage, adverse effects)
- Carcinoma, Transitional Cell
(drug therapy, pathology)
- Cisplatin
(administration & dosage, adverse effects)
- Deoxycytidine
(administration & dosage, adverse effects, analogs & derivatives)
- Female
- Glomerular Filtration Rate
(drug effects)
- Humans
- Kidney
(drug effects, pathology)
- Male
- Middle Aged
- Prognosis
- Progression-Free Survival
- Treatment Outcome
- Urinary Bladder Neoplasms
(drug therapy, pathology)
- Urothelium
(drug effects, pathology)
- Gemcitabine
|